BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model.

Journal of Neurochemistry
Tetsushi KatauraMasaya Imoto

Abstract

Bilirubin, the end product of heme redox metabolism, has cytoprotective properties and is an essential metabolite associated with cardiovascular disease, inflammatory bowel disease, type 2 diabetes, and neurodegenerative diseases including Parkinson's disease (PD). PD is characterized by progressive degeneration of nigral dopaminergic neurons and is associated with elevated oxidative stress due to mitochondrial dysfunction. In this study, using a ratiometric bilirubin probe, we revealed that the mitochondrial inhibitor, rotenone, which is widely used to create a PD model, significantly decreased intracellular bilirubin levels in HepG2 cells. Chemical screening showed that BRUP-1 was a top hit that restored cellular bilirubin levels that were lowered by rotenone. We found that BRUP-1 up-regulated the expression level of heme oxygenase-1 (HO-1), one of the rate-limiting enzyme of bilirubin production via nuclear factor erythroid 2-related factor 2 (Nrf2) activation. In addition, we demonstrated that this Nrf2 activation was due to a direct inhibition of the interaction between Nrf2 and Kelch-like ECH-associated protein 1 (Keap1) by BRUP-1. Both HO-1 up-regulation and bilirubin restoration by BRUP-1 treatment were significantly ab...Continue Reading

References

Mar 26, 1998·Experimental Neurology·H M SchipperE G Stopa
Nov 26, 1998·Microscopy Research and Technique·H M Schipper
May 2, 2001·Nature Reviews. Neuroscience·M F Beal
Jul 20, 2002·Blood·Viktória JeneyGyörgy Balla
Aug 24, 2002·Proceedings of the National Academy of Sciences of the United States of America·Albena T Dinkova-KostovaPaul Talalay
Oct 3, 2002·The EMBO Journal·Jiying SunKazuhiko Igarashi
Jan 4, 2003·The Journal of Biological Chemistry·Tomomi KitamuroShigeki Shibahara
Mar 26, 2003·Human Molecular Genetics·J Paul TaylorKenneth H Fischbeck
Sep 25, 2003·The Journal of Biological Chemistry·Hiroshi SuzukiKazuhiko Igarashi
Nov 25, 2003·The Journal of Biological Chemistry·Mikiei TanakaM Maral Mouradian
Mar 20, 2004·Nature Reviews. Drug Discovery·Kevin J BarnhamAshley I Bush
Jun 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Teru HideshimaKenneth C Anderson
Jun 25, 2005·Toxicological Sciences : an Official Journal of the Society of Toxicology·Rebekah J JakelJeffrey A Johnson
Sep 19, 2006·American Journal of Respiratory Cell and Molecular Biology·Stefan W RyterAugustine M K Choi
Sep 28, 2006·Journal of Biochemistry and Molecular Biology·Ebenezer Olatunde Farombi, Young Joon Surh
Jan 6, 2007·Journal of Neuropathology and Experimental Neurology·Chenere P RamseyKelly L Jordan-Sciutto
Jan 29, 2008·Current Medicinal Chemistry·J A OlzmannL S Chin
Feb 2, 2008·The Journal of Biological Chemistry·Melanie TheodoreIfeanyi J Arinze
Mar 18, 2008·Journal of Neurology, Neurosurgery, and Psychiatry·J Jankovic
Feb 3, 2009·The Journal of Biological Chemistry·Truyen NguyenCecil B Pickett
Mar 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Thomas W SedlakSolomon H Snyder
Feb 4, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Jung-Woo BaeSeok-Yong Lee
Jun 8, 2010·BMC Cell Biology·Izumi YanatoriFumio Kishi
Aug 14, 2010·Current Drug Targets·Agnieszka Jazwa, Antonio Cuadrado
Dec 6, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·Shinji SaikiNobutaka Hattori
Feb 4, 2012·Cold Spring Harbor Protocols·Andrea L Szymczak-WorkmanDario A A Vignali
Feb 16, 2012·The Journal of Biological Chemistry·Ana S AlmeidaHelena L A Vieira
Mar 23, 2012·Frontiers in Pharmacology·Thomas Jansen, Andreas Daiber
May 3, 2012·Medicinal Research Reviews·Sadagopan MageshLongqin Hu
May 25, 2012·Molecular Neurobiology·Koichi WakabayashiHitoshi Takahashi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.